Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/8/2018 |
| Start Date: | April 2015 |
| End Date: | October 2016 |
Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers (PELICAN)
About 1 million individuals in the US have a prescription for supplemental oxygen (O2). Using
O2 can prolong life and increase quality of life. Patients often do not use their oxygen as
prescribed, which means that they are not benefiting as much as they could be from this
therapy. The purpose of this study is to evaluate whether a PEer-Led O2 Infoline for patients
and CAregivers (PELICAN) will increase adherence to supplemental oxygen prescription and
improve health in patients with chronic obstructive pulmonary disease (COPD).
O2 can prolong life and increase quality of life. Patients often do not use their oxygen as
prescribed, which means that they are not benefiting as much as they could be from this
therapy. The purpose of this study is to evaluate whether a PEer-Led O2 Infoline for patients
and CAregivers (PELICAN) will increase adherence to supplemental oxygen prescription and
improve health in patients with chronic obstructive pulmonary disease (COPD).
The COPD Foundation operates a peer-led telephone-based information line, but its
effectiveness in promoting adherence to O2 therapy and patient-centered outcomes is unknown.
Our overall hypothesis is that a patient-centered Peer-Led O2 InfoLine for patients and
CAregivers (PELICAN) will increase adherence and improve health. We have developed a
broad-based collaboration with patients/caregivers, advocacy groups, a national O2 supplier,
and others to conduct a 3-arm pragmatic clinical trial, to evaluate the comparative
effectiveness of proactive vs. reactive PELICAN interventions vs. usual care on adherence to
O2 (primary outcome) and on other patient-centered outcomes (secondary outcomes).
effectiveness in promoting adherence to O2 therapy and patient-centered outcomes is unknown.
Our overall hypothesis is that a patient-centered Peer-Led O2 InfoLine for patients and
CAregivers (PELICAN) will increase adherence and improve health. We have developed a
broad-based collaboration with patients/caregivers, advocacy groups, a national O2 supplier,
and others to conduct a 3-arm pragmatic clinical trial, to evaluate the comparative
effectiveness of proactive vs. reactive PELICAN interventions vs. usual care on adherence to
O2 (primary outcome) and on other patient-centered outcomes (secondary outcomes).
Inclusion Criteria:
1. Age 18 years or older.
2. Physician diagnosis of COPD
3. Physician prescription for home O2 for 24hrs/day, 7 days/week
4. Willing to use home O2.
5. Working telephone number.
Exclusion Criteria:
1. Unable to read and speak English.
2. Discharge to home hospice or expected survival less than 6 months.
We found this trial at
6
sites
Chicago, Illinois 60612
Principal Investigator: Jerry A Krishnan, MD, PhD
Phone: 844-627-5587
Click here to add this to my saved trials
National Jewish Health National Jewish Health is known worldwide for treatment of patients with respiratory,...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials